Company intelligence / Profile preview

Praha Vaccines

Bohumil, Czech Republic

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Praha Vaccines was acquired by Novavax in 2020 to provide large-scale vaccine and biologics manufacturing capacity, primarily for COVID-19 vaccines using recombinant nanoparticle technology and Matrix-M adjuvant. NVX-CoV2373 (COVID-19 vaccine) was in late-stage clinical trials at time of transaction.[1][4]

Therapeutic areas: Infectious Diseases
Modalities: VaccineBiologic
Industry: Contract Manufacturing Organization

Partnerships

Serum Institute of IndiaNovavaxCoalition for Epidemic Preparedness Innovations (CEPI)

Beyond the preview

Go deeper on Praha Vaccines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Praha Vaccines.

Explore the full profile